Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up StudyIan W Flinn, Richard van der Jagt, Brad Kahl, et al.
Nature Communications|August 24, 2016
Sixteen years of change in the global terrestrial human footprint and implications for biodiversity conservationOscar Venter, Eric W Sanderson, Ainhoa Magrach, et al.
Scientific Data|August 24, 2016
Global terrestrial Human Footprint maps for 1993 and 2009Oscar Venter, Eric W Sanderson, Ainhoa Magrach, et al.
BMJ Paediatrics Open|June 6, 2024
Developing a data repository to support interdisciplinary research into childhood stunting: a UKRI GCRF Action Against Stunting Hub protocol paperKaitlin Conway-Moore, Darius Tetsa Tata, Peter Wood, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell LymphomaColm Keane, Clare Gould, Kimberley Jones, et al.
Blood|March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyIan W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Research Square|April 10, 2023
Biochemical activity induced by a germline variation in KLK3 (PSA) associates with cellular function and clinical outcome in prostate cancerSrilakshmi Srinivasan, Thomas Kryza, Nathalie Bock, et al.
Nature Communications|November 6, 2024
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancerSrilakshmi Srinivasan, Thomas Kryza, Nathalie Bock, et al.
Pageof 13